Current Filters

Showing 81 - 90 results of 3488

Fidaxomicin (Dificid) (Last Updated: Jul 11, 2012)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Dificid
Manufacturer:
Optimer Pharmaceuticals Canada, Inc.
Submission Type:
Initial
Indications:

Clostridium difficile infection

Lurasidone (Latuda) (Last Updated: Jul 3, 2012)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Latuda
Manufacturer:
Sunovion Pharmaceuticals Inc.
Submission Type:
Initial
Indications:

schizophrenia

Asenapine (Saphris) (Last Updated: Dec 12, 2011)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Saphris
Manufacturer:
Lundbeck Canada Inc.
Submission Type:
Initial
Indications:

Bipolar I disorder

Mometasone/formoterol (Zenhale) (Last Updated: Jun 6, 2012)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Zenhale
Manufacturer:
Merck Canada Inc.
Submission Type:
Request For Advice
Indications:

Asthma maintenance (adults, children 12 or older)

Saxagliptin (Onglyza) (Last Updated: May 28, 2012)

Project Line:
Reimbursement Review
Project Status:
Withdrawn
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Onglyza
Manufacturer:
Bristol-Myers Squibb / AstraZeneca Canada Inc.
Submission Type:
Resubmission
Indications:

Diabetes mellitus (Type 2)

Fesoterodine fumarate (Toviaz) (Last Updated: Apr 27, 2012)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Toviaz
Manufacturer:
Pfizer Canada Inc.
Submission Type:
Initial
Indications:

Bladder, overactive

Doxycycline monohydrate (Apprilon) (Last Updated: Apr 27, 2012)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Apprilon
Manufacturer:
Galderma Canada Inc.
Submission Type:
Initial
Indications:

Rosacea treatment

Colesevelam hydrochloride (Lodalis) (Last Updated: Apr 27, 2012)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Lodalis
Manufacturer:
Valeant Canada LP
Submission Type:
Initial
Indications:

Hypercholesterolemia

Ranibizumab injection (Lucentis) (Last Updated: Apr 25, 2012)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Lucentis
Manufacturer:
Novartis Pharmaceuticals Canada Inc.
Submission Type:
Initial
Indications:

Macular edema, secondary to retinal vein occlusion

Fampridine (Fampyra) (Last Updated: Apr 16, 2012)

Project Line:
Reimbursement Review
Project Status:
Complete
Contains:
Brand Name Manufacturer Submission Type Indications

Brand Name:
Fampyra
Manufacturer:
Biogen Idec Canada Inc.
Submission Type:
Initial
Indications:

Multiple Sclerosis, improve walking disability

Download results as CSV